Validire Patricia, Capovilla Mathieu, Asselain Bernard, Kirova Youlia, Goudefroye Rémi, Plancher Corine, Fourquet Alain, Zanni Manuela, Gaulard Philippe, Vincent-Salomon Anne, Decaudin Didier
Department of Clinical Hematology, Institut Curie, Paris, France.
Am J Hematol. 2009 Mar;84(3):133-9. doi: 10.1002/ajh.21353.
The aims of this study were to define the initial pathological and clinical characteristics, and prognostic factors of patients with primary breast malignant lymphoma (PBL). All patients treated at the Institut Curie for lymphoma with breast involvement were reviewed. A pathological review of all cases was performed. Forty-five cases were selected in whom 38 cases were of diffuse large B-cell lymphoma. A complete analysis was then performed on these 38 patients. Twenty out of 28 cases (71%) of cases were Bcl-2 positive and four out of 28 (14%) had a CD10 positive staining. Peculiar initial characteristics showed nodal involvement in 58% of the cases and two or more extra-nodal sites in 31% of the cases. Among the 37 patients for whom all data were available, and according to the International Prognostic Index, 19 patients (51%) were classified in the low-risk group, 5 cases (14%) in the low- to intermediate-risk group, 6 patients (16%) in the intermediate- to high-risk group, and 7 (19%) case in the high-risk group. At the end of initial therapy, 34 patients (89%) achieved CR. With a median follow-up of 96 months, 18 patients (47%) relapsed of whom 3 had a relapse in central nervous system site. The 5-year disease-free (DFS) and overall survivals (OS) were 54% and 61%, respectively. In multivariate analysis, the presence of 2 or more extranodal sites was prognostic for lower DFS (P = 0.0008) and OS (P = 0.09), and a performance status > or = 1 was prognostic for lower OS (P = 0.005). Finally, when our series was compared with a historical series of 111 patients with aggressive nodal lymphomas, we observed significant lower survival rates in localized PBL (P < 0.03). Initial breast localization has a pejorative impact on the outcome of patients with Non-Hodgkin's Lymphoma (NHL), with an impressive adverse influence of additional extranodal sites. These results suggest a specific management of NHL with breast involvement.
本研究的目的是明确原发性乳腺恶性淋巴瘤(PBL)患者的初始病理和临床特征以及预后因素。对居里研究所治疗的所有有乳腺受累的淋巴瘤患者进行了回顾。对所有病例进行了病理复查。选取了45例病例,其中38例为弥漫性大B细胞淋巴瘤。然后对这38例患者进行了全面分析。28例病例中有20例(71%)Bcl-2阳性,28例中有4例(14%)CD10染色阳性。特殊的初始特征显示,58%的病例有淋巴结受累,31%的病例有两个或更多结外部位受累。在所有数据均可用的37例患者中,根据国际预后指数,19例患者(51%)被归类为低风险组,5例(14%)为低至中风险组,6例患者(16%)为中至高风险组,7例(19%)为高风险组。初始治疗结束时,34例患者(89%)达到完全缓解(CR)。中位随访96个月时,18例患者(47%)复发,其中3例在中枢神经系统部位复发。5年无病生存率(DFS)和总生存率(OS)分别为54%和61%。多因素分析显示,存在两个或更多结外部位对较低的DFS(P = 0.0008)和OS(P = 0.09)具有预后意义,体能状态≥1对较低的OS具有预后意义(P = 0.005)。最后,当将我们的系列与111例侵袭性淋巴结淋巴瘤的历史系列进行比较时,我们观察到局限性PBL患者的生存率显著较低(P < 0.03)。初始乳腺定位对非霍奇金淋巴瘤(NHL)患者的预后有不良影响,额外的结外部位有显著的不利影响。这些结果提示对有乳腺受累的NHL应进行特殊管理。